121 related articles for article (PubMed ID: 20946921)
1. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.
Kopecka J; Campia I; Olivero P; Pescarmona G; Ghigo D; Bosia A; Riganti C
J Control Release; 2011 Jan; 149(2):196-205. PubMed ID: 20946921
[TBL] [Abstract][Full Text] [Related]
2. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
[TBL] [Abstract][Full Text] [Related]
3. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.
Doublier S; Riganti C; Voena C; Costamagna C; Aldieri E; Pescarmona G; Ghigo D; Bosia A
Mol Cancer Res; 2008 Oct; 6(10):1607-20. PubMed ID: 18922976
[TBL] [Abstract][Full Text] [Related]
4. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
5. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
Zheng Z; Aojula H; Clarke D
J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
[TBL] [Abstract][Full Text] [Related]
6. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells.
Gatouillat G; Odot J; Balasse E; Nicolau C; Tosi PF; Hickman DT; López-Deber MP; Madoulet C
Cancer Lett; 2007 Nov; 257(2):165-71. PubMed ID: 17517470
[TBL] [Abstract][Full Text] [Related]
7. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.
Polimeni M; Voena C; Kopecka J; Riganti C; Pescarmona G; Bosia A; Ghigo D
Biochem J; 2011 Oct; 439(1):141-9. PubMed ID: 21679161
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.
Riganti C; Miraglia E; Viarisio D; Costamagna C; Pescarmona G; Ghigo D; Bosia A
Cancer Res; 2005 Jan; 65(2):516-25. PubMed ID: 15695394
[TBL] [Abstract][Full Text] [Related]
9. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
Angelini A; Di Ilio C; Castellani ML; Conti P; Cuccurullo F
J Biol Regul Homeost Agents; 2010; 24(2):197-205. PubMed ID: 20487633
[TBL] [Abstract][Full Text] [Related]
10. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
12. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
Carrion C; de Madariaga MA; Domingo JC
Life Sci; 2004 Jun; 75(3):313-28. PubMed ID: 15135652
[TBL] [Abstract][Full Text] [Related]
15. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
16. Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin.
Panneerselvam M; Bredehorst R; Vogel CW
Cancer Res; 1987 Sep; 47(17):4601-7. PubMed ID: 3621156
[TBL] [Abstract][Full Text] [Related]
17. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells.
Sauer I; Dunay IR; Weisgraber K; Bienert M; Dathe M
Biochemistry; 2005 Feb; 44(6):2021-9. PubMed ID: 15697227
[TBL] [Abstract][Full Text] [Related]
18. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
19. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
20. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
